Activities related to solid state properties in late clinical development include:
• Crystallization optimization
• Impact of scale or manufacturing changes on particle form or attributes
• Out of specification investigations
• Dissolution changes caused by API form or particle attributes?
• Full understand of crystal form space in API and Drug Product
• Setting of specifications
• Particle size? Form?
Click to visit resource in a new window. These resources can include Webinars, Publications, Whitepapers and Publications. Please check back often for the latest updates. This page will stay open in a separate tab so you can return.